CytomX Therapeutics Inc
CTMX
Get informed when a big investor buys or sells
+ FollowMarket Cap$600.86M
Close$
$6.51
134.3% upside
Current Fair Value
134.3% upsideUndervalued by 134.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $600.86 Million |
|---|---|
| Enterprise Value | $613.41 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.15 |
| Beta | 2.14 |
| Outstanding Shares | 218,939,423 |
Return
| Return on Equity | -26.37% |
|---|---|
| Return on Assets | -20.89% |
| Return on Invested Capital | -24.60% |
Valuation & Multiples
| P/E Ratio | -6.13 |
|---|---|
| PEG | -0.05 |
| Price to Sales | - |
| Price to Book Ratio | 2.78 |
| Enterprise Value to Revenue | 33.52 |
| Enterprise Value to EBIT | -7.3 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$12.39 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$10.43 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4674▼ 20.66% |
|---|---|
| Total Calls | 1,263,400▼ 51.39% |
| Total Puts | 590,500▼ 66.29% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 97.56%▼ 11.41% |
|---|---|
| Total Invested | $801.10M▼ 11.76% |
| Investors Holding | 189▼ 2.00% |
ESG Score
No data
About CytomX Therapeutics Inc
CEO: Sean McCarthy